Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis

Open access
Singh, Siddharth, Fumery, Mathurin, Singh, Abha G., Singh, Namrata, Prokop, Larry J., Dulai, Parambir S., Sandborn, William J., Curtis, Jeffrey R. · 2020 · Arthritis Care & Research

Abstract

Objective: We performed a systematic review and meta‐analysis to evaluate the comparative effects of tumor necrosis factor inhibitors (TNF i), non‐TNF i biologics, and conventional synthetic disease‐modifying antirheumatic drugs (cs DMARD s) on cardiovascular risk in rheumatoid arthritis (RA). Methods: Using a systematic search through May 8, 2018, we included 14 observational studies in adults with RA treated with TNF i, non‐TNF i biologics, tofacitinib, or cs DMARD s, reporting the risk of major adverse cardiovascular events (MACE) or stroke. Only studies reporting active comparators were included. We performed random effects meta‐analysis and estimated odds ratios (OR s) and 95% confidence intervals (95% CI s). Results: As compared to TNF i, tocilizumab was associated with a decreased risk of MACE (OR 0.59 [95% CI 0.34–1.00]), whereas cs DMARD s were associated with an increased risk of MACE (cs DMARD s including methotrexate OR 1.45 [95% CI 1.09–1.93]; without methotrexate OR 2.57 [95% CI 1.32–5.00]), without heterogeneity (I 2 = 0%); there was no difference in risk of MACE between abatacept and TNF i (OR 0.89 [95% CI 0.71–1.11]), or between tocilizumab and abatacept (OR 0.81 [0.57–1.16]). Based on 11 cohorts (n = 135,053 patients), as compared to TNF i, cs DMARD s were associated with an increased risk of stroke (OR 1.17 [95% CI 1.01–1.36]); there was no difference in risk of stroke between different biologics (tocilizumab versus TNF i OR 0.98 [95% CI 0.59–1.61]; abatacept versus TNF i OR 1.08 [0.86–1.34]; tocilizumab versus abatacept OR 0.73 [95% CI 0.39–1.38]), without heterogeneity (I 2 = 0%). No comparative studies on cardiovascular risk with tofacitinib were identified. Conclusion: Based on meta‐analysis, as compared to TNF i, tocilizumab may be associated with a reduced risk of MACE, whereas cs DMARD s may be associated with an increased risk of MACE and stroke.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.23875

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 158

Metadata

Authors
Singh, S., Fumery, M., Singh, A. G., Singh, N., Prokop, L. J., Dulai, P. S., Sandborn, W. J., & Curtis, J. R.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2020-03-27
Volume
72
Issue
4
Pages
561-576
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W2921889468
Cited by
158
References
5
FWCI
5.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.